Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.55 |
| ▸ | CLK2 | P49760 | 2/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.55 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.55 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.55 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 5/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932287 | 0.78 | MAPK14 (0.50) | ALOX5 | |
| SCHEMBL2929915 | 0.77 | KIT (0.44) | GSK3BMAP4K4CLK4CSNK1DCSNK1E | |
| SCHEMBL1386747 | 0.74 | KIT (0.44) | GSK3BMAP4K4CLK4CSNK1DCSNK1E | |
| SCHEMBL1384452 | 0.74 | ERBB2 (0.47) | GSK3BMAP4K4CLK4CSNK1DADORA2A | |
| SCHEMBL7139723 | 0.74 | MAPK14 (0.65) | GSK3BCDK2MAP4K4CLK2CDK5 | |
| SCHEMBL8043069 | 0.72 | GSK3B (0.52) | GSK3BCDK2MAP4K4CLK2CDK5 | |
| SCHEMBL5377558 | 0.72 | LRRK2 (0.62) | DYRK1ACSNK1D | |
| SCHEMBL2928014 | 0.69 | MAPK14 (0.46) | GSK3BCDK2CDK5GSK3ACSNK1D | |
| SCHEMBL20675707 | 0.69 | ADORA2A (0.51) | CSNK1DCSNK1EADORA2AADORA2BADORA1 | |
| SCHEMBL29652642 | 0.69 | MAPK14 (0.56) | GSK3BMAP4K4CLK4CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| CN-100354275-C | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2007-12-12 | — | — | CN | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| CN-1753894-A | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2006-03-29 | — | — | CN | claimed |
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | Poolbeg Pharma (UK) Limited (GB) | 2025-01-09 | — | — | US | disclosed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | disclosed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | disclosed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| EP-3478322-B1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| CN-100354275-C | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2007-12-12 | — | — | CN | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| CN-1753894-A | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2006-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, MAPK1 | GSK3B 634/4885CDK2 1058/4885MAP4K4 69/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | GSK3B 649/4885CDK2 1154/4885MAP4K4 69/4885 |
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | GSK3B 1601/4885CDK2 69/4885MAP4K4 24/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | GSK3B 1958/4885CDK2 114/4885MAP4K4 32/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | GSK3B 649/4885CDK2 1154/4885MAP4K4 69/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | GSK3B 634/4885CDK2 1058/4885MAP4K4 69/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | GSK3B 1958/4885CDK2 114/4885MAP4K4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.